tbuckley/cabot-search huggingface dataset:
Chlorophyll Derived from Chlorella Inhibits Dioxin Absorption from the Gastrointestinal Tract and Accelerates Dioxin Excretion in Rats
Authors: Kunimasa Morita, Masahiro Ogata, Takashi Hasegawa
Journal: Environmental Health Perspectives (2001)

We investigated the effects of chlorophyll derived from Chlorella on gastrointestinal absorption of seven types of polychlorinated dibenzo-p-dioxin (PCDD) and 10 types of polychlorinated dibenzofuran (PCDF) in Wistar rats. Twenty-eight rats were randomly distributed into seven groups (n = 4). After overnight food deprivation, rats were given 4 g of the basal diet or 4 g of the chlorophyll diet containing 0.01-0.5% chlorophyll one time on day 1; each diet also contained 0.2 mL PCDD and PCDF standard solutions. The amounts of fecal excretion of PCDD and PCDF congeners from days 1 to 5 in the group fed 0.01% chlorophyll were 64.8% for 1,2,3,7,8-pentaCDD, 78.6% for 1,2,3,4,7,8-hexaCDD, 73.5% for 1,2,3,6,7,8-hexaCDD, 58.5% for 1,2,3,7,8,9-hexaCDD, 33.3% for 1,2,3,4,6,7,8-heptaCDD, 85.7% for 1,2,3,7,8-pentaCDF, 77.3% for 2,3,4,7,8-pentaCDF, 88.6% for 1,2,3,4,7,8-hexaCDF, 78.0% for 1,2,3,6,7,8-hexaCDF, 62.5% for 1,2,3,7,8,9-hexaCDF, 84.1% for 2,3,4,6,7,8-hexaCDF, 41.7% for 1,2,3,4,6,7,8-heptaCDF, and 40.0% for 1,2,3,4,6,7,8-heptaCDF greater (p < 0.01) than those of the control group, respectively. The fecal excretion of PCDD and PCDF congeners was remarkably increased along with the increasing dietary chlorophyll. The amounts of PCDD and PCDF congeners in rats on day 5 administered dioxin mixtures were lower in the 0.01% chlorophyll group than in the control group, ranging from 3.5 to 50.0% for PCDD congeners and from 3.7 to 41.7% lower for PCDF congeners, except for 2,3,7,8-tetrachlorodibenzofuran. The amount of PCDD and PCDF congeners in rats was remarkably decreased along with the increasing dietary chlorophyll. These findings suggest that chlorophyll is effective for preventing dioxin absorption via foods.
Facteur prédictif de récidive hémorragique précoce après traitement endoscopique chez des patients ayant une hémorragie ulcéreuse avec des lésions à haut risque
Authors: D Maggio, A Barkun, M Martel, S Elouali, I Gralnek
Journal: Endoscopy (2013)

Dans une période où l'on souhaite raccourcir les durées d'hospitalisation, nous n'avons pas assez de données sur les facteurs prédictifs de récidive hémorragique après traitement endoscopique chez les patients ayant une hémorragie digestive haute d'origine ulcéreuse (HDHU), et présentant des lésions classées à haut risque de récidive (LHR). Le but de cette étude était d'évaluer les facteurs prédictifs de la récidive hémorragique précoce, avant la fin des 72 heures de perfusion d'un inhibiteur de la pompe à proton (IPP).
Consultants for The Journal in 1970
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
Authors: D. Herchenhorn, F. L. Dias, C. M. Araújo, C. G. Ferreira, M. Bezerra, P. Hermont, R. A. Lima, A. L. Porto, C. G. Pereira, R. G. Martins
Journal: Journal of Clinical Oncology (2005)

5596 Background: Phase I/II study of Erlotinib combined with Cisplatin and Radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Methods: This is a phase I study, in SCCHN patients (pts) with stages III and IV. Pts received therapy with RT 70.2Gy in 8 weeks and Cisplatin(C) 100mg/m2, 3 doses every 3 weeks, both starting on Day 8. Erlotinib (E) was started on Day 1, continued until the end of RT, and escalated in cohorts of 3 pts/dose level: level 1–50mg, level 2–100mg and level 3–150mg. For grade IV toxicity leading to RT interruption, 3 additional pts were included in the same dose level. Frozen tissue for molecular studies was collected before and after treatment will be analyzed together with tissue from pts in the phase II study that will follow. Results: Seven pts were treated until now, 1 was excluded early due to inadequate compliance, 3 completed treatment in level 1 (50mg) and 3 in level 2 (100mg). Median age was 56 years, 5 patients had larynx cancer (stage III 1pt, IVA 2 pts, IVB 2 pts) and 1 oropharynx (stage III). In 2 pts the dose of C had to be reduced or withheld due to ototoxicity (1 pt in each level). Other grade III toxicity included nausea in 2 pts, dermatitis, respiratory infection, neutropenia and mucositis in 1 pt, all in level 1. There was no grade 4 toxicity leading to delay in RT. All 4 pts evaluated had complete pathological responses (2 pts not available yet). Five pts had clinical benefit (objective tumor reduction or symptom improvement) after 7 days on Erlotinib alone. Conclusions: This is the first report of the combination of Erlotinib, Cisplatin and Radiotherapy in squamous cell carcinoma of head and neck. Final results of the phase I will be presented at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech, Roche
Editorial: Antipsychiatrists and ECT.
Journal: BMJ (1975)

Antipsychiatrists and ECTAmong the effects of the wide publicity given to criticisms of current psychiatric methods by the "antipsychiatrists" has been increasing reluctance to acknowledge the value of physical treatments such as electroconvulsive therapy-ECT.This attitude, more prominent in the United States than Britain, was well illustrated by a recent article' in the American Journal of Psychiatry by a young medical graduate undergoing psychiatric training.He described the management of his father's involutional depression, an illness perhaps precipitated by reserpine.Outpatient care and efforts at treatment in three hospitals of good reputation with psychotherapy, family therapy, therapeutic community methods, and drugs (un- specified) all failed to help.After admission, much against his son's wishes, to a fourth hospital "of marginal repute" the father rapidly recovered with ECT.In common with many of his contemporaries, the young psychiatrist had regarded ECT as a barbarous and outdated treatment for which there were no clear indications.How has this attitude arisen ?For the first 20 years from its invention by Cerletti and Bini in 1938 ECT had the field to itself.Until the introduction ofeffective antidepressant drugs in 1958 it was the sole success- ful treatment for endogenous (involutional) depression.It could also cut short attacks of acute mania and was valuableand still is-in managing individual symptoms of both depres- sive and other illnesses: refusal of food, stupor, severe lack of sleep, and intractable itching and scratching.ECT is safe- safer still with the now almost universal modification by muscle relaxant drugs and brief anaesthesia-quick in producing a response, and remarkably free from serious side effects; any alternative would have to be very good to rival it.Antidepressant drugs, particularly the tricyclic group, have advantages.They are successful in a wider spectrum of dis- orders, but they are much less effective in really severe attacks with retardation, mutism, refusal of food, and depressive delusions.The failure rate2 of all antidepressants is 10-30%.They may also produce side effects, some of which, such as urinary retention and cardiac arrhythmias, may be dangerous.But it is the delay before satisfactory response begins that is their chief disadvantage.This delay not only prolongs suffering and lengthens the period during which suicide may be a risk but can also have economic drawbacks-for example, increasing the time off work.In the United States Hippius2 noted that despite "a reluctance to resort" to ECT an increased use has been made of it to shorten the illness because of health insur-
Abstract 806: Mitochondrial oncobioenergetic Index (MOBI) mediated by oxidative stress as a marker for progression from indolent to aggressive cancer
Authors: Praveen Kumar Vayalil
Journal: Cancer Research (2019)

Abstract Cellular Metabolic profile is governed by the way which the mitochondria functions in a cell. Any change in mitochondrial function would alter the cellular metabolic profile. During the evolution of tumor from onset to aggressive cancer, the metabolic needs also differs as alterations in oncogenes, tumor suppressor genes, and changes in the epigenetics and microenvironment occurs at each stage of the tumorigenesis process. Therefore, we hypothesized that mitochondrial function will be stably and dynamically altered at each stage of the tumor development. Moreover, the ability mitochondria to withstand stress will also be different. We recently defined MOBI, which is a mathematical representation of oncobioenergetic profile of a cancer cell. MOBI increases significantly upon transformation into localized premalignant form and rapidly falls below the normal as they become aggressive. We also show that the MOBI of cancer cells at various stages of tumorigenesis after oxidative stress depend on their initial MOBI. Aggressive cancer cells completely lost their MOBI upon stress, even though some of the cancer cells had high initial reserve capacity. However, cells from pre-malignant cells had significantly higher MOBI than the normal epithelial cells. This study thus reveals that MOBI could be a potential biomarker to distinguish aggressive cancer from that of indolent disease and screening of compounds that specifically target the bioenergetics of cancer cells. Citation Format: Praveen Kumar Vayalil. Mitochondrial oncobioenergetic Index (MOBI) mediated by oxidative stress as a marker for progression from indolent to aggressive cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 806.
Maternal exposure to potential teratogens
Authors: J. J. Nora
Journal: JAMA (1967)

A prospective study of 240 mothers observed until delivery reveals a high frequency of exposure to potential teratogens in the first trimester of pregnancy (mean exposure per mother, 3.7 potentially teratogenic agents). Although some exposures are unavoidable, the great majority of these exposures, including radiation and drugs, would be considered readily avoidable. The mean experience in the first trimester was 3.1 drug exposures per mother, which emphasizes not only that drug exposures are common, but that they are frequently multiple. Drugs used by the mothers were most often obtained by prescription. The significance of the role of teratogens in human malformations is not clearly established. However, until adequate information is available, it is appropriate to emphasize the magnitude of drug and other potentially teratogenic exposures to pregnant women and to enlist the support of physicians in the reduction of this exposure.
Manuscripts Approved for JNCI, December 1971-January 1972
Journal: JNCI Journal of the National Cancer Institute (1972)

Journal Article Manuscripts Approved for JNCI, December 1971-January 1972 Get access JNCI: Journal of the National Cancer Institute, Volume 48, Issue 2, February 1972, Pages 575–576, https://doi.org/10.1093/jnci/48.2.575-a Published: 01 February 1972
Toxicity and Health Effects of Selected Organotin Compounds: A Review
Authors: Renate D. Kimbrough
Journal: Environmental Health Perspectives (1976)

The toxicity of selected tin compounds is reviewed. Over the years, a variety of uses has been found for organic and inorganic tin compounds, as fungicides, as stablizers in plastics, moluscicides, and miticides; they have also been suggested as insect chemosterilants and for other industrial uses. Many of these products are unpalatable when mixed into diets and have been suggested as rodent repellents. Inhaling tin as dust or fumes may cause a benign pneumoconiosis in exposed workers. The organotin compounds can be divided into alkyltin and aryltin compounds. The trimethyl and triethyltin compounds are well absorbed from the gastrointestinal tract and are the most toxic in this group. Triethyltin particularly produces status spongiosus of the white matter of the central nervous system. Most of the other alkyl and aryl tin compounds are poorly absorbed from the gastrointestinal tract, and are less toxic when given orally than when given parentally. Only one compound, tricyclohexyltin hydroxide, is now registered by the Environmental Protection Agency as a miticide. This product produces skin irritation in rabbits. Studies should be conducted to determine whether it causes contact dermatitis in humans.
Chronic dialysis and the Tower of Babel
Authors: L. B. Berman
Journal: JAMA (1974)

FROM the earliest days of chronic dialysis (1960), the problem that would not go away was lack of beds and money. The formation of "life or death" committees who chose patients to be treated or rejected was one result. Quotas on the number of indigent patients to be treated was another. The word "indigent" had a very special meaning in dealing with treatment programs that cost up to $25,000 per year, per patient. Americans customarily deal with important issues by passing 50 sets of laws. Thus, chronic dialysis joined some strange bedfellows such as divorce, gambling, and alcohol in that it became a matter of great importance as to which state of the union you chose in which to become uremic: New York, California, and Illinois were good places to lose your kidney function. A great many nephrologists worked long and hard to achieve support for<i>all</i>who needed dialysis.
STRAIN, TRAUMA, AND HEART DISEASE
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
195P Irinotecan plus cetuximab (Cmab) versus irinotecan plus panitumumab (Pmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) as third-line in daily practice
Authors: N. Sugimoto, A. Hasegawa, F. Fujisawa, T. Yoshinami, T. Yagi, F. Imamura
Journal: Annals of Oncology (2016)
Transmission
Authors: James W. Girardy
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: W. LAMERS
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article BOOK REVIEWS Get access On Death Without Dignity: The Human Impact of Technological Dying, Perspectives on Death and Dying Series . David Wendell Moller . Amity-ville, N.Y. : Baywood Publ. Co., Inc. , 1990 , 116 pp. $16.50. WILLIAM LAMERS WILLIAM LAMERS 9510 Yerba Buena Rd. Malibu, CA 90265 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 20, 16 October 1991, Pages 1500–1501, https://doi.org/10.1093/jnci/83.20.1500-a Published: 16 October 1991
BOOK REVIEWS
Authors: B. J. BROOKS
Journal: JNCI Journal of the National Cancer Institute (1992)

BOOK REVIEWS Get access Manual of Oncologic Therapeutics 1991/1992 Robert E. Wittes , ed. Philadelphia : J. B. Lippincott , 1991 . 478 pp., illus. $39.50. ISBN 0-397-51140-X BURKE J. BROOKS, JR. BURKE J. BROOKS, JR. Ochsner Clinic of Baton Rouge16777 Medical Center Dr. Baton Rouge, LA 70816 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 10, 20 May 1992, Page 807, https://doi.org/10.1093/jnci/84.10.807 Published: 20 May 1992
Development of Anti-tumor Immunity against a Non-immunogenic Mammary Carcinoma through Somatic GM-CSF, IL-2, and HSVtk Combination Gene Therapy
Authors: D BROCKSTEDT, M DIAGANA, Y ZHANG, K TRAN, N BELMAR, M MEIER, A YANG, F BOISSIERE, A LIN, Y CHIANG
Journal: Molecular Therapy (2002)

Gene therapy for cancer using suicide genes such as the herpes simplex virus thymidine kinase gene (HSVtk) has been explored extensively in preclinical and clinical studies. We have improved the use of HSVtk by combining it with two cytokine genes encoding granulocyte/macrophagecolony-stimulating factor (GM-CSF) and interleukin-2 (IL-2), and determined their additive/synergistic effects on tumor regression and inhibition of metastases in the non-immunogenic, spontaneously metastatic mammary tumor model, 4T1. Two adenoviral vectors (AV) were constructed, one carrying HSVtk (AV-TK) and the second (AV-GM/IL2) carrying Gm-CSf and Il2. Only the combination of AV-TK/GCV and AV-GM/IL2 showed a significant decrease in tumor growth and reduction of distant metastases with 25% of the tumors undergoing complete regression. When surgical excision of primary tumors was included in the regimen, local treatment with AV-TK/GCV plus AV-GM/IL2 further enhanced long-term survival. A fraction of the treated mice developed anti-tumor immunity and survived a second challenge with 4T1. Functional analyses demonstrated infiltration of lymphocytes within the tumor and a strong tumor-specific cytotoxic T lymphocyte response in TK- plus cytokine-treated animals. These data indicate that the coexpression of GM-CSF and IL-2 can augment the effect of HSVtk suicide gene therapy.
Alphabetic index to abstract authors
Authors: Aalberse Rob, Abraham William, Milena Acencio, Yoko Adachi, Asdis Adalsteinsdottir, Elva Adalsteinsdottir, Jennifer Adamski, Brigitte Adessi, Atef Akhras, Waleed A1-Herz, Lara Theresa, Allergovigilance Networks, Jacquelyn Allwein, Johan Alm, Mafia Almeida, Catarina Almqvist, Susan Alters, Talissa Altes, Gaylene Altman, Altman Leonard, Altznauer Frank, Ana Ameal, Agnes Andaya, Applebaum Nachman, Andrea Apter, Siti Arif, Nermina Arifhodzick, Sonia Arredondo, Vikram Arya, Ahmet Asan, Philip Askenase, Michael Asmus, Maria Baeza, John Bagu, Nerin Bahceciler, Abdul Bahrainwala, James Baker, Mauro Baldini, Jane Balent, Giorgio Ballardini, Zuhair Ballas, Edward Barrett, Kathleen Bartemes, Joan Bartra, Norberto Bassan, Christopher Bates, Mary Bates, Vijay Batra, Simona Battucci, Laurie Bauman, Aruna Behera, Sharon Behman, Jaap Beintema, Juan Beitia, Joseph Bellanti, Joe Belleau, Nathalie Bellerose, Clifford Bellone, Nadia Belloni, Dante Beltramo, Ben-Joseph Rami, Brian Berendts, William Berger, David Bergman, Eva Berkes, Berkun Yakov, Mario Bermejo, Barbara Bienkiewicz, Izabela Bogus-Buczyfiska, Marina Bogush, Betty Bohner, Mary Bouinger, Patrizia Bonadonna, Elizabeth Bonagura, Vincent Bonagura, Attilio Boner, Maria Bono, Erik Bonten, James Boozan, Michael Borchers, Christopher Brightling, Edward Brooks, Gregory Brooks, Danny Brown, Eleanor Brown, Joanna Brown, Kevin Brown, Linda Brown, Louise Brown, Margaret Brown, Timothy Brown, Bruijnzeel -Koomen, Brtining Thomas, Stefanie Bruns, Jean-Marie Bruzzese, Patricia Buchanan, Daniela Bundschuh, David Burt
Journal: Journal of Allergy and Clinical Immunology (2002)